Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1469-1473

  Beyazit, Yavuz ^a   Kekilli, Murat ^a   Ibis, Mehmet ^a   Kurt, Mevlut ^a   Sayilir, Abdurrahim ^a   Onal, Ibrahim Koral ^a   Purnak, Tugrul ^b   Oztas, Erkin ^a   Tas, Adnan ^a   Yesil, Yusuf ^a   Arhan, Mehmet ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Malignancy; Obstructive jaundice; Red cell distribution width

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BILE DUCT CANCER; BILE DUCT OBSTRUCTION; BILE DUCT TUMOR; BLOOD CELL COUNT; BRUSH CYTOLOGY; CANCER CYTODIAGNOSIS; CHOLANGIOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OBSTRUCTIVE JAUNDICE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RED CELL DISTRIBUTION WIDTH; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLEDOCHOLITHIASIS; COMMON BILE DUCT NEOPLASMS; CONSTRICTION, PATHOLOGIC; ERYTHROCYTE INDICES; ERYTHROCYTES; FEMALE; GALLBLADDER NEOPLASMS; HEPATIC DUCT, COMMON; HUMANS; JAUNDICE, OBSTRUCTIVE; KLATSKIN'S TUMOR; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SPHINCTER OF ODDI; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865160098     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10676     Document Type: Article

References (34)

1. Kurt M, Onal IK, Parlak E, et al.: Do metabolic alterations serve as biochemical markers in the diagnosis of malignant biliary obstruction? An observational study. Eur J Gastroenterol Hepatol 2010; 22:58-60.
2. Saluja SS, Sharma R, Pal S, Sahni P, Chattopadhyay TK: Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford) 2007; 9:373-382.
3. Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33:266-270.
4. Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000; 26:474-479.
5. Romero Artaza J, Carbia CD, Ceballo MF, Diaz NB: Red cell distribution width (RDW): its use in the characterization of microcytic and hypochromic anemias. Medicina (B Aires) 1999; 59:17-22.
6. Ozkalemkas F, Ali R, Ozkocaman V, et al.: The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases. BMC Cancer 2005; 5:144.
7. Spell DW, Jones DV Jr, Harper WF, David Bessman J: The value of a complete blood count in predicting cancer of the colon. Cancer Detect Prev 2004; 28:37-42.
8. Maruyama S, Hirayama C, Yamamoto S, et al.: Red blood cell status in alcoholic and non-alcoholic liver disease. J Lab Clin Med 2001; 138:332-337.
9. Felker GM, Allen LA, Pocock SJ, et al.: Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50:40-47.
10. Hawes RH: Diagnostic and therapeutic uses of ERCP in pancreatic and biliary tract malignancies. Gastrointest Endosc 2002; 56(6):S201-205.
11. Bilbao MK Dotter CT, Lee TG, Katon RM: Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology 1976; 70:314-320.
12. Sherman S, Ruffolo TA, Hawes RH, Lehman GA: Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and non-dilated bile ducts. Gastroenterology 1991; 101:1068-1075.
13. Scudera PL, Koizumi J, Jacobson IM: Brush cytology evaluation of lesions encountered during ERCP. Gastrointest Endosc 1990; 36:281-284.
14. Dixon LR: The complete blood count: physiologic basis and clinical usage The complete blood count: physiologic basis and clinical usage. J Perinat Neonatal Nurs 1997; 11:1-18.
15. Clarke K, Sagunarthy R, Kansal S: RDW as an additional marker in inflammatory bowel disease/undifferentiated colitis. Dig Dis Sci 2008; 53:2521-2523.
16. Lippi G, Filippozzi L, Salvagno GL, et al.: Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009; 133:1441-1443.
17. Evans TC, Jehle D: The red blood cell distribution width. J Emerg Med 1991; 9(1):71-74.
18. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM: Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 2009; 169:515-523.
19. Douglas SW, Adamson JW: The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975; 45:55-65.
20. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
21. Pierce CN, Larson DF: Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. Perfusion 2005; 20:83-90.
22. Piagnerelli M, Boudjeltia KZ, Brohee D, et al.: Alterations of red blood cell shape and sialic acid membrane content in septic patients. Crit Care Med 2003; 31:2156-2162.
23. Kiefer CR, Snyde, LM: Oxidation and erythrocyte senescence. Curr Opin Hemato 2000; 7:113-116.
24. Paritpokee N, Tangkijvanich P, Teerasaksilp S, et al.: Fast liver alkaline phosphatase isoenzyme in diagnosis of malignant biliary obstruction. J Med Assoc Thai 1999; 82:1241-1246.
25. Jain AK, Tantry BV, Kumar A, Gupta JP: Alkaline phosphatase isoenzymes in the differential diagnosis of cholestasis. Trop Gastroenterol 1986; 7:65-70.
26. Bain VG, Abraham N, Jhangri GS, et al.: Prospective study of biliary strictures to determine the predictors of malignancy. Can J Gastroenterol 2000; 14:397-402.
27. Al-Mofleh IA, Aljebreen AM, Al-Amri SM, et al.: Biochemical and radiological predictors of malignant biliary strictures. World J Gastroenterol 2004; 10:1504-1507.
28. Pasanen P, Pikkarainen P, Alhava E, Partanen K, Penttila I: Value of serum alkaline phosphatase, aminotransferases, gamma-glutamyl transferase, leucine aminopeptidase, and bilirubin in the distinction between benign and malignant diseases causing jaundice and cholestasis: results from a prospective study. Scand J Clin Lab Invest 1993; 53:35-39.
29. Kim HJ, Kim MH, Myung SJ, et al.: A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94:1941-1946.
30. Bjornsson E, Kilander A, Olsson R: CA19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999; 19:501-508.
31. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108:865-869.
32. Basso D, Meggiato T, Fabris C, et al.: Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Eur J Clin Invest 1992; 22:800-804.
33. Collazos J, Genolla J, Ruibal A: CA19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin Chim Acta 1992; 210:145-151.
34. Akdogan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B: Are serum and biliary carcinoembryonic antigen and carbohydrate antigen 19-9 determinations reliable for differentiation between benign and malignant biliary disease? Turk J Gastroenterol 2003; 14:181-184.